@article{452e319766e744e5a542c11affac537e,
title = "Widespread brain tau and its association with ageing, Braak stage and Alzheimer{\textquoteright}s dementia",
abstract = "Autopsy data have proposed that a topographical pattern of tauopathy occurs in the brain with the development of dementia due to Alzheimer{\textquoteright}s disease. We evaluated the findings of tau-PET to better understand neurofibrillary tangle development as it is seen in cognitively unimpaired and impaired individuals. The evolution of Alzheimer{\textquoteright}s disease tauopathy in cognitively unimpaired individuals needs to be examined to better understand disease pathogenesis. Tau-PET was performed in 86 cognitively impaired individuals who all had abnormal amyloid levels and 601 cognitively unimpaired individuals. Tau-PET findings were assessed for relationships with clinical diagnosis, age, and regional uptake patterns relative to Braak stage. Regional and voxel-wise analyses were performed. Topographical findings from tau-PET were characterized using hierarchical clustering and clinical characteristic-based subcategorization. In older cognitively unimpaired individuals (550 years), widespread, age-related elevated tau signal was seen among those with normal or abnormal amyloid status as compared to younger cognitively unimpaired individuals (30–49 years). More frequent regional tau signal elevation throughout the brain was seen in cognitively unimpaired individuals with abnormal versus normal amyloid. Elevated tau signal was seen in regions that are considered high Braak Stage in cognitively unimpaired and cognitively impaired individuals. Hierarchical clustering and clinical characteristic-based categorizations both showed different patterns of tau signal between groups such as greater tau signal in frontal regions in younger onset Alzheimer{\textquoteright}s disease dementia participants (most of whom had a dysexecutive clinical presentation). Tau-PET signal increases modestly with age throughout the brain in cognitively unimpaired individuals and elevated tau is seen more often when amyloid brain accumulation is present. Tau signal patterns in cognitively unimpaired correspond to early Braak stage but also suggest tangle involvement in extra-medial temporal and extra-temporal regions that are considered more advanced in the Braak scheme even when amyloid negative. Our findings also suggest the possibility of widespread development of early tangle pathology rather than a pattern defined exclusively by adjacent, region-to-region spread, prior to onset of clinical symptoms. Distinct patterns of neurofibrillary tangle deposition in younger-onset Alzheimer{\textquoteright}s disease dementia versus older-onset Alzheimer{\textquoteright}s disease dementia provide evidence for variability in regional tangle deposition patterns and demonstrate that different disease phenotypes have different patterns of tauopathy. Pathological correlation with imaging is needed to assess the implications of these observations.",
author = "Lowe, {Val J.} and Wiste, {Heather J.} and Senjem, {Matthew L.} and Weigand, {Stephen D.} and Therneau, {Terry M.} and Boeve, {Bradley F.} and Josephs, {Keith A.} and Ping Fang and Pandey, {Mukesh K.} and Murray, {Melissa E.} and Kejal Kantarci and Jones, {David T.} and Prashanthi Vemuri and Jonathan Graff-Radford and Schwarz, {Christopher G.} and Machulda, {Mary M.} and Mielke, {Michelle M.} and Roberts, {Rosebud O.} and Knopman, {David S.} and Petersen, {Ronald C.} and Jack, {Clifford R.}",
note = "Funding Information: We would like to greatly thank AVID Radiopharmaceuticals, Inc., for their support in supplying the AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation needed for this work. This research was supported by NIH grants, P50 AG016574, R01 NS89757, R01 NS089544, R01 DC10367, U01 AG006786, R21 NS094489, by the Robert Wood Johnson Foundation, The Elsie and Marvin Dekelboum Family Foundation, The Liston Family Foundation and by the Robert H. and Clarice Smith and Abigail van Buren Alzheimer{\textquoteright}s Disease Research Program, The GHR Foundation, Foundation Dr Corinne Schuler and the Mayo Foundation. Funding Information: V.J.L consults for Bayer Schering Pharma, Piramal Life Sciences and Merck Research and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals and the NIH (NIA, NCI). P.F. receives research support from GE Healthcare, Siemens Molecular Imaging, AVID. B.F.B receives royalties from the publication of Behavioral Neurology of Dementia, serves on the Scientific Advisory Board for the Tau Consortium, and receives research support from GE Healthcare, Axovant Sciences, the NIH, and the Mangurian Foundation. K.A.J. receives research support from the NIH (NIDCD NINDS and NIA). K.K. receives research grants from the NIH/NIA. M.M.Ma. receives research support from the NIH (NIA and NIDCD). M.M.Mi receives research support from the NIH/NIA, Department of Defense, and Biogen and consults for Lysosomal Therapeutics, Inc., and Eli Lilly & Company. R.O.R. receives research support from the NIH and a research grant from F. Hoffman-La Roche. D.S.K. serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals, Biogen and the Alzheimer{\textquoteright}s Disease Cooperative Study; and receives research support from the NIH. R.C.P. is a consultant for Biogen, Roche, Inc., Merck, Inc. and Genentech, Inc.; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), and receives research support from the National Institute of Health. C.R.J. receives research support from the NIH/ NIA, and the Alexander Family Alzheimer{\textquoteright}s Disease Research Professorship of the Mayo Foundation. Funding Information: This research was supported by NIH grants, P50 AG016574, R01 NS89757, R01 NS089544, R01 DC10367, U01 AG006786, R21 NS094489, by the Robert Wood Johnson Foundation, The Elsie and Marvin Dekelboum Family Foundation, The Liston Family Foundation and by the Robert H. and Clarice Smith and Abigail van Buren Alzheimer{\textquoteright}s Disease Research Program, The GHR Foundation, Foundation Dr Corinne Schuler and the Mayo Foundation. Publisher Copyright: {\textcopyright} The Author (2017). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.",
year = "2018",
month = jan,
day = "1",
doi = "10.1093/brain/awx320",
language = "English (US)",
volume = "141",
pages = "271--287",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "1",
}